[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Liberty Medical Solutions, LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":108},{"warningLetters":4,"total":107},[5,31,51,72,92],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},3123,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-29T04:00:00Z\">09\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-chemical-solutions-llc-616672-09292021\">True Chemical Solutions, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Permit Access to or Copying of Records","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Travis Pitcock\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>True Chemical Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6215 W. County Road 112\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Midland\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>79706\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-21-60\u003C\u002Fp>\n\n\u003Cp>September 29, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Pitcock:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products listed include HAPPY HANDS Hand Sanitizer Topical Gel with Moisturizing Solution. On November 10, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered, as did numerous telephone calls from the Agency regarding this matter, so the Agency sent a follow-up written request for such records and other information by certified return-receipt mail on May 4, 2021. Delivery was confirmed by your signature, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\u003C\u002Fp>\n\n\u003Cp>Since declaration of the COVID-19 public health emergency,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> a number of hand sanitizer products have been recalled due to quality issues ranging from substitution with other drug substances to subpotency.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>We note that, while your firm is registered with the FDA as a manufacturer of OTC drug products, your website indicates your firm is also involved in pipeline operations and fracturing, also known as fracking. Fracking operations typically involve multiple chemicals that could be harmful to patients if they were to contaminate drugs, such as your hand sanitizers.\u003C\u002Fp>\n\n\u003Cp>Respond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\u003C\u002Fp>\n\n\u003Cp>The Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>Continued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>You may provide additional information for our consideration as we continue to assess your activities and practices.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016866715 and ATTN: Marisa Heayn.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The HHS Declaration of a Public Health Emergency is available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Travis Pitcock\n\nRecipient Title\n\nChief Executive Officer\n\nTrue Chemical Solutions, LLC\n\n6215 W. County Road 112\n\nMidland, TX 79706\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-60\n\nSeptember 29, 2021\n\nDear Mr. Pitcock:\n\nYour firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products listed include HAPPY HANDS Hand Sanitizer Topical Gel with Moisturizing Solution. On November 10, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered, as did numerous telephone calls from the Agency regarding this matter, so the Agency sent a follow-up written request for such records and other information by certified return-receipt mail on May 4, 2021. Delivery was confirmed by your signature, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\n\nSince declaration of the COVID-19 public health emergency,1 a number of hand sanitizer products have been recalled due to quality issues ranging from substitution with other drug substances to subpotency.2 The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nWe note that, while your firm is registered with the FDA as a manufacturer of OTC drug products, your website indicates your firm is also involved in pipeline operations and fracturing, also known as fracking. Fracking operations typically involve multiple chemicals that could be harmful to patients if they were to contaminate drugs, such as your hand sanitizers.\n\nRespond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\n\nThe Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\n\nContinued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nYou may provide additional information for our consideration as we continue to assess your activities and practices.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nIdentify your response with FEI 3016866715 and ATTN: Marisa Heayn.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\n__________________________\n\n1 The HHS Declaration of a Public Health Emergency is available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx.\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance.","True Chemical Solutions, LLC","true-chemical-solutions-llc-616672-09292021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-chemical-solutions-llc-616672-09292021","2026-10-26T08:10:15.483298+00:00","Warning Letter","Issued","2021-10-05","616672","Drugs","Mr. Travis Pitcock","2026-08-20T02:35:09.615+00:00","VIA UPS","2021-09-29",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":18,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":37,"recipient_name":48,"body_fetched_at":49,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},3235,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2021-08-03T13:20:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-26T04:00:00Z\">07\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021\">Lexion Medical LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick Spearman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lexion Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>545 Atwater Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pspearman@lexionmedical.com\"> pspearman@lexionmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 26, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Patrick Spearman:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&amp;feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AP 50\u002F30 Insufflator and Insuflow Port\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\u003C\u002Fp>\n\n\u003Cp>For example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\u003C\u002Fp>\n\n\u003Cp>• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\u003Cbr>\n “Less hypothermia”\u003Cbr>\n “Less peritoneal damage”\u003Cbr>\n “Less postoperative pain”\u003Cbr>\n “Decreased amount of pain medication”\u003Cbr>\n “Shortened recovery room stay”\u003Cbr>\n “Less tissue dessication”\u003Cbr>\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\u003C\u002Fp>\n\n\u003Cp>There are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pneuview XE\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\u003C\u002Fp>\n\n\u003Cp>• “Eliminate \u003Cem>all\u003C\u002Fem> plume, gases, and particles” [emphasis added]\u003Cbr>\n• “…eliminating \u003Cem>all\u003C\u002Fem> harmful contaminants associated with combustion, including viral particles” [emphasis added]\u003Cbr>\n• “actively evacuates and removes \u003Cem>all \u003C\u002Fem>smoke plume including hazardous gas” [emphasis added]\u003Cbr>\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\u003C\u002Fp>\n\n\u003Cp>The cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\u003Cbr>\n\u003Cbr>\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\u003C\u002Fp>\n\n\u003Cp>• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\u003Cbr>\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\u003Cbr>\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\u003C\u002Fp>\n\n\u003Cp>We are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\u003C\u002Fp>\n\n\u003Cp>Additionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\u003C\u002Fp>\n\n\u003Cp>• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\u003Cbr>\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\u003Cbr>\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\u003Cbr>\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\u003Cbr>\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\u003Cbr>\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\u003C\u002Fp>\n\n\u003Cp>Taken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>In combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>FDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC\u003Cbr>\nShelly Amann, Owner\u003Cbr>\nLexion Medical LLC\u003Cbr>\n545 Atwater Circle\u003Cbr>\nSaint Paul, MN 55103\u003Cbr>\nsamann@lexionmedical.com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. \u003Cem>J Robot Surg\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), \u003Cem>available\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick Spearman\n\nRecipient Title\n\nOwner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nUnited States\n\npspearman@lexionmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nJuly 26, 2021\n\nRE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Patrick Spearman:\n\nThe United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\n\nUnder section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nAP 50\u002F30 Insufflator and Insuflow Port\n\nThe AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\n\nFor example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\n\n• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\n\n “Less hypothermia”\n\n “Less peritoneal damage”\n\n “Less postoperative pain”\n\n “Decreased amount of pain medication”\n\n “Shortened recovery room stay”\n\n “Less tissue dessication”\n\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\n\nThere are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\n\nPneuview XE\n\nThe Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\n\n• “Eliminate all plume, gases, and particles” [emphasis added]\n\n• “…eliminating all harmful contaminants associated with combustion, including viral particles” [emphasis added]\n\n• “actively evacuates and removes all smoke plume including hazardous gas” [emphasis added]\n\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\n\nThe cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\n\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\n\n• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\n\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”2 (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\n\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\n\nWe are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\n\nAdditionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-193 in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\n\n• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\n\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\n\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\n\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\n\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\n\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\n\nTaken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\n\nIn combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.4 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.5 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nFDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\n\nYour firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nNote, there are two response time frames specified. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\n\nYour firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\n\nPlease refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\n\nFinally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC\n\nShelly Amann, Owner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nsamann@lexionmedical.com\n\n______________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. J Robot Surg.\n\n3 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n4 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n5 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Lexion Medical LLC","lexion-medical-llc-613588-07262021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021","2026-10-26T08:09:14.12601+00:00","2021-08-03","613588","Medical Devices","Patrick Spearman","2026-08-20T02:44:07.37+00:00","2021-07-26",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":26,"closeout_date":19,"issuing_office":57,"recipient_name":68,"body_fetched_at":69,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":71,"medical_device_id":19,"response_letter_date":19},1227,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2024-10-01T13:20:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-06T04:00:00Z\">09\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024\">Clean Solutions LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Asim Ozcan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Clean Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>791 Paulison Ave., Suite 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Clifton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07011-3608\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:asim@cleansolutionsnj.com\"> asim@cleansolutionsnj.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003Cbr>\nCMS #686995\u003C\u002Fp>\n\n\u003Cp>9\u002F6\u002F2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ozcan:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\u003C\u002Fp>\n\n\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>Without adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cp>• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\u003Cbr>\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\u003Cbr>\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\u003Cbr>\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\u003Cbr>\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003Cbr>\n\u003Cbr>\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOPQO Division I\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Asim Ozcan\n\nRecipient Title\n\nPresident\n\nClean Solutions LLC\n\n791 Paulison Ave., Suite 5\n\nClifton, NJ 07011-3608\n\nUnited States\n\nasim@cleansolutionsnj.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter\n\nCMS #686995\n\n9\u002F6\u002F2024\n\nDear Mr. Ozcan:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\n\nYour firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\n\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nWithout adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\n• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\n\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\n\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\n\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\n\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nIn response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\n\nIf you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOPQO Division I\n\nU.S. Food and Drug Administration","Clean Solutions LLC","clean-solutions-llc-686995-09062024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024","2026-10-26T08:08:15.745138+00:00","2024-10-01","686995","Mr. Asim Ozcan","2026-08-19T22:31:53.814+00:00","VIA Electronic Mail","2024-09-06",{"id":73,"raw":74,"subject":79,"body_html":80,"body_text":81,"firm_name":82,"letter_id":83,"created_at":63,"fei_number":19,"letter_url":84,"updated_at":85,"action_type":22,"case_status":23,"posted_date":86,"marcs_cms_no":87,"product_type":26,"closeout_date":19,"issuing_office":78,"recipient_name":88,"body_fetched_at":89,"delivery_method":90,"recipient_title":19,"reference_number":19,"action_taken_date":91,"medical_device_id":19,"response_letter_date":19},1338,[75,76,77,78,79,13,13,13],"\u003Ctime datetime=\"2024-07-30T13:20:00Z\">07\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-25T04:00:00Z\">07\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskin-beauty-solutions-683006-07252024\">Skin Beauty Solutions\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Finished Pharmaceuticals\u002FUnapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Cassandra Pryor\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Skin Beauty Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>P.O. Box 25527\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55125-0527\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@skinbeautysolutions.com\"> info@skinbeautysolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 25, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 683006\u003C\u002Fp>\n\n\u003Cp>Dear Cassandra Pryor:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website, at the internet address https:\u002F\u002Fwww.skinbeautysolutions.com\u002F in April 2024 and has observed that your website offers numerous chemical peel drug products; including, multiple strengths of lactic acid, glycolic acid, combination glycolic and lactic acid, and salicylic acid products\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, including “LACTIC Acid Skin Chemical Peel 90%,” “GLYCOLIC ACID Skin Cosmetic Grade Peel 70%,” “Combination Peel GLYCOLIC 35% LACTIC 45%,” and “SALICYLIC ACID Skin Chemical Peel 30%” (hereinafter referred to as your “chemical peels”) for sale in the United States. As described below, your chemical peels are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>The Agency is concerned about potent chemical peel products that are available to be purchased and used by consumers. Such products pose a public health risk because they can cause skin injuries such as burns on the area of application, wounds, pain, swelling, and scarring. FDA has received adverse event reports of injuries involving use of such products, some of which required emergency room care, specialty care from a dermatologist, and\u002For surgical intervention.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, your firm’s chemical peels are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website https:\u002F\u002Fwww.skinbeautysolutions.com\u002F that establish the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>LACTIC Acid Skin Chemical Peel 90%\u003C\u002Fu>\u003Cbr>\n• “lactic acid skin peel 90%\u003Cbr>\nClears Acne &amp; Scars\u003Cbr>\nRemoves Dead Skin Cells”\u003C\u002Fp>\n\n\u003Cp>• “Chemical peels work by loosening and gently sloughing off the damaged, unattractive skin cells. . .. Lactic Peels can also work on the deeper layers of skin to accelerate the skin’s natural production of collagen and elastin.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>GLYCOLIC ACID Skin Cosmetic Grade Peel 70%\u003C\u002Fu>\u003Cbr>\n• “glycolic acid skin peel 70%\u003Cbr>\nClears Acne &amp; Scars\u003Cbr>\nRemoves Dead Skin Cells\u003Cbr>\nPrevents Fine lines &amp; Wrinkles”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Combination Peel GLYCOLIC 35% LACTIC 45%\u003C\u002Fu>\u003Cbr>\n• “combination peel\u003Cbr>\nGlycolic Acid 35%\u003Cbr>\nLactic Acid 45%\u003Cbr>\nClears Acne &amp; Scars\u003Cbr>\nRemoves Dead Skin Cells\u003Cbr>\nSmoothes [sic] Fine lines &amp; Wrinkles”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>SALICYLIC ACID Skin Chemical Peel 30%\u003C\u002Fu>\u003Cbr>\n• “salicylic acid skin peel 30%\u003Cbr>\nRemoves Blackheads\u003Cbr>\nClears Acne &amp; Scars”\u003C\u002Fp>\n\n\u003Cp>• “SALICYLIC ACID SKIN CHEMICAL PEEL W\u002F BETA HYDROXY (BHA) BY SKIN BEAUTY SOLUTIONS – IDEAL FOR ACNE, BLACKHEADS, DERMATITIS, WHITEHEADS, CLOGGED PORES.”\u003C\u002Fp>\n\n\u003Cp>Your chemical peels are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We have observed that your website offers Lactic Acid skin peel 35%, 50%, 70%, 90% strengths, Glycolic Acid skin peel buffered and unbuffered 35%, 50%, 70% strengths, combination Glycolic Acid 35% and Lactic Acid 45% strength, and Salicylic Acid skin chemical peels 10%, 20%, and 30% strengths.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nCassandra Pryor\n\nRecipient Title\n\nManager\n\nSkin Beauty Solutions\n\nP.O. Box 25527\n\nSaint Paul, MN 55125-0527\n\nUnited States\n\ninfo@skinbeautysolutions.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nJuly 25, 2024\n\nRE: 683006\n\nDear Cassandra Pryor:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website, at the internet address https:\u002F\u002Fwww.skinbeautysolutions.com\u002F in April 2024 and has observed that your website offers numerous chemical peel drug products; including, multiple strengths of lactic acid, glycolic acid, combination glycolic and lactic acid, and salicylic acid products1, including “LACTIC Acid Skin Chemical Peel 90%,” “GLYCOLIC ACID Skin Cosmetic Grade Peel 70%,” “Combination Peel GLYCOLIC 35% LACTIC 45%,” and “SALICYLIC ACID Skin Chemical Peel 30%” (hereinafter referred to as your “chemical peels”) for sale in the United States. As described below, your chemical peels are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\n\nThe Agency is concerned about potent chemical peel products that are available to be purchased and used by consumers. Such products pose a public health risk because they can cause skin injuries such as burns on the area of application, wounds, pain, swelling, and scarring. FDA has received adverse event reports of injuries involving use of such products, some of which required emergency room care, specialty care from a dermatologist, and\u002For surgical intervention.\n\nUnapproved New Drugs\n\nBased on a review of your website, your firm’s chemical peels are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims observed on your website https:\u002F\u002Fwww.skinbeautysolutions.com\u002F that establish the intended use of these products as drugs include, but may not be limited to, the following:\n\nLACTIC Acid Skin Chemical Peel 90%\n\n• “lactic acid skin peel 90%\n\nClears Acne & Scars\n\nRemoves Dead Skin Cells”\n\n• “Chemical peels work by loosening and gently sloughing off the damaged, unattractive skin cells. . .. Lactic Peels can also work on the deeper layers of skin to accelerate the skin’s natural production of collagen and elastin.”\n\nGLYCOLIC ACID Skin Cosmetic Grade Peel 70%\n\n• “glycolic acid skin peel 70%\n\nClears Acne & Scars\n\nRemoves Dead Skin Cells\n\nPrevents Fine lines & Wrinkles”\n\nCombination Peel GLYCOLIC 35% LACTIC 45%\n\n• “combination peel\n\nGlycolic Acid 35%\n\nLactic Acid 45%\n\nClears Acne & Scars\n\nRemoves Dead Skin Cells\n\nSmoothes [sic] Fine lines & Wrinkles”\n\nSALICYLIC ACID Skin Chemical Peel 30%\n\n• “salicylic acid skin peel 30%\n\nRemoves Blackheads\n\nClears Acne & Scars”\n\n• “SALICYLIC ACID SKIN CHEMICAL PEEL W\u002F BETA HYDROXY (BHA) BY SKIN BEAUTY SOLUTIONS – IDEAL FOR ACNE, BLACKHEADS, DERMATITIS, WHITEHEADS, CLOGGED PORES.”\n\nYour chemical peels are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n___________________\n\n1 We have observed that your website offers Lactic Acid skin peel 35%, 50%, 70%, 90% strengths, Glycolic Acid skin peel buffered and unbuffered 35%, 50%, 70% strengths, combination Glycolic Acid 35% and Lactic Acid 45% strength, and Salicylic Acid skin chemical peels 10%, 20%, and 30% strengths.","Skin Beauty Solutions","skin-beauty-solutions-683006-07252024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskin-beauty-solutions-683006-07252024","2026-10-26T08:09:58.469498+00:00","2024-07-30","683006","Cassandra Pryor","2026-08-19T23:55:45.859+00:00","Via Email","2024-07-25",{"id":93,"raw":94,"subject":97,"body_html":98,"body_text":99,"firm_name":100,"letter_id":101,"created_at":18,"fei_number":19,"letter_url":102,"updated_at":103,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":104,"product_type":47,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":105,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":106,"medical_device_id":19,"response_letter_date":19},3127,[8,95,96,37,97,13,13,13],"\u003Ctime datetime=\"2021-08-09T04:00:00Z\">08\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021\">Pairon Solutions LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Pairon Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13970 SW 72nd Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Portland\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97223\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:melissa@paironsolutions.com\"> melissa@paironsolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: August 9, 2021\u003Cbr>\n\u003Cbr>\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White &amp; Black)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White &amp; Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White &amp; Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Statements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Statements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Statements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White &amp; Black) that they provide “&gt;95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Statements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Based on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White &amp; Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>In addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false or misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Representations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that Pairon 3Ply Face Masks (Blue, White &amp; Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Unauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon&nbsp;3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Wayborn Quality &amp; Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>To date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White &amp; Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database merely denotes that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector\u003Cbr>\nDivision of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Yabo Zhang\u003Cbr>\nDongguan Arun Industrial, Co., Ltd.\u003Cbr>\nNO.18Xingfeng St, Changlong, Huangjiang\u003Cbr>\nDongguan, CN 523766\u003C\u002Fp>\n\n\u003Cp>US Agent:\u003Cbr>\nSimcal\u003Cbr>\nUCL-REG SERVICE INC.\u003Cbr>\n3907 Prince Street Suite 6F\u003Cbr>\nFlushing, NY 11354\u003Cbr>\nEmail: gbstandard@163.com\u003C\u002Fp>\n\n\u003Cp>UCL-Reg Service\u003Cbr>\n602 ROCKWOOD ROAD, WILMINGTON\u003Cbr>\nNew Castle, DE, 19802\u003C\u002Fp>\n\n\u003Cp>XIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\u003Cbr>\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\u003Cbr>\nHubei Province, P.R. China\u003Cbr>\nXiantao, CN 433018\u003C\u002Fp>\n\n\u003Cp>Leeyeo Kee\u003Cbr>\nRegrek LLC\u003Cbr>\n19 Holly Cove Ln.\u003Cbr>\nDover, DE 19901\u003Cbr>\nEmail: regrek.cs@hotmail.com\u003C\u002Fp>\n\n\u003Cp>Sungo Technical Services Inc.\u003Cbr>\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\u003Cbr>\nE-mail：sungo.group@yahoo.com\u003Cbr>\nEmail: Shage2008@126.com\u003C\u002Fp>\n\n\u003Cp>WUXI HINGDOU SPORTS CO., LTD\u003Cbr>\nHongdou Industrial Park, Donggang Town\u003Cbr>\nWuxi, Jiangsu, 214000, China\u003C\u002Fp>\n\n\u003Cp>Director: Crane Yu\u003Cbr>\nWayborn Quality &amp; Technology Services\u003Cbr>\n306, Xincheng International Main Building,\u003Cbr>\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\u003Cbr>\nEmail: wayborn@wayb.org\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>)\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nPairon Solutions LLC\n\n13970 SW 72nd Ave\n\nPortland, OR 97223\n\nUnited States\n\nmelissa@paironsolutions.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: August 9, 2021\n\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White & Black)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White & Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White & Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\n\nStatements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nStatements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nStatements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White & Black) that they provide “>95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nStatements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\n\nBased on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White & Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\n\nYour website contains a number of false or misleading representations, including but not limited to:\n\nRepresentations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo1 on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nRepresentations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nRepresentations that Pairon 3Ply Face Masks (Blue, White & Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nUnauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon 3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\n\nDisplaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo1 and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nDisplaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nDisplaying a “Certification of Registration” issued by “Wayborn Quality & Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\n\nTo date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White & Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database merely denotes that the establishment has provided certain information to FDA.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector\n\nDivision of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nYabo Zhang\n\nDongguan Arun Industrial, Co., Ltd.\n\nNO.18Xingfeng St, Changlong, Huangjiang\n\nDongguan, CN 523766\n\nUS Agent:\n\nSimcal\n\nUCL-REG SERVICE INC.\n\n3907 Prince Street Suite 6F\n\nFlushing, NY 11354\n\nEmail: gbstandard@163.com\n\nUCL-Reg Service\n\n602 ROCKWOOD ROAD, WILMINGTON\n\nNew Castle, DE, 19802\n\nXIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\n\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\n\nHubei Province, P.R. China\n\nXiantao, CN 433018\n\nLeeyeo Kee\n\nRegrek LLC\n\n19 Holly Cove Ln.\n\nDover, DE 19901\n\nEmail: regrek.cs@hotmail.com\n\nSungo Technical Services Inc.\n\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\n\nE-mail：sungo.group@yahoo.com\n\nEmail: Shage2008@126.com\n\nWUXI HINGDOU SPORTS CO., LTD\n\nHongdou Industrial Park, Donggang Town\n\nWuxi, Jiangsu, 214000, China\n\nDirector: Crane Yu\n\nWayborn Quality & Technology Services\n\n306, Xincheng International Main Building,\n\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\n\nEmail: wayborn@wayb.org\n\n___________________________\n\n1 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy)","Pairon Solutions LLC","pairon-solutions-llc-616392-08092021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021","2026-10-26T08:09:39.952179+00:00","616392","2026-08-20T02:35:05.169+00:00","2021-08-09",5,{"510k":109,"classification":110,"enforcement":111,"event":112,"event_backfill":113,"pma":114,"warning_letter":115},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-19T04:00:36.695+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]